Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Neonc Technologies, Inc.
Bristol-Myers Squibb
Aulos Bioscience, Inc.
ImmunityBio, Inc.
Mayo Clinic
University of Pittsburgh
University of Pittsburgh
7 Hills Pharma, LLC
Incyte Corporation
Toray Industries, Inc
Sarcoma Oncology Research Center, LLC
University of California, San Diego
Eli Lilly and Company
Molecular Templates, Inc.
Biomica Ltd.
UNICANCER
University Hospital, Ghent
Rutgers, The State University of New Jersey
HUYABIO International, LLC.
Fate Therapeutics
Nektar Therapeutics
Nektar Therapeutics
Jules Bordet Institute
Incyte Corporation
University College, London
Duke University
Genocea Biosciences, Inc.
Bristol-Myers Squibb
Sheba Medical Center
MultiVir, Inc.
Bristol-Myers Squibb